Reviva Pharmaceuticals I... (RVPH)
Reviva Pharmaceuticals Statistics
Share Statistics
Reviva Pharmaceuticals has 46.58M shares outstanding. The number of shares has increased by 56.22% in one year.
Shares Outstanding | 46.58M |
Shares Change (YoY) | 56.22% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 22.87% |
Shares Floating | 41.63M |
Failed to Deliver (FTD) Shares | 1.48K |
FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 5.3M, so 11.37% of the outstanding shares have been sold short.
Short Interest | 5.3M |
Short % of Shares Out | 11.37% |
Short % of Float | 12.72% |
Short Ratio (days to cover) | 19.04 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.19. Reviva Pharmaceuticals's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -2.19 |
PS Ratio | 0 |
Forward PS | 0.2 |
PB Ratio | 21.43 |
P/FCF Ratio | -4.33 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Reviva Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.
Current Ratio | 1.38 |
Quick Ratio | 1.38 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-2,617.4B |
Employee Count | 15 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | -16.95B |
Effective Tax Rate | 43188.89% |
Stock Price Statistics
The stock price has increased by -82.13% in the last 52 weeks. The beta is -0.1, so Reviva Pharmaceuticals's price volatility has been lower than the market average.
Beta | -0.1 |
52-Week Price Change | -82.13% |
50-Day Moving Average | 1.49 |
200-Day Moving Average | 1.35 |
Relative Strength Index (RSI) | 19.59 |
Average Volume (20 Days) | 1.47M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -39,503.6B |
Net Income | -39,260.8B |
EBITDA | -39,503.6B |
EBIT | -39.24M |
Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has 23.37M in cash and 0 in debt, giving a net cash position of 23.37M.
Cash & Cash Equivalents | 23.37M |
Total Debt | 0 |
Net Cash | 23.37M |
Retained Earnings | -134.35M |
Total Assets | 7.63M |
Working Capital | -10.72M |
Cash Flow
In the last 12 months, operating cash flow was -28.32M and capital expenditures 0, giving a free cash flow of -28.32M.
Operating Cash Flow | -28.32M |
Capital Expenditures | 0 |
Free Cash Flow | -28.32M |
FCF Per Share | -1.19 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RVPH does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for RVPH is $9.5, which is 1432.3% higher than the current price. The consensus rating is "Buy".
Price Target | $9.5 |
Price Target Difference | 1432.3% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Scores
Altman Z-Score | -40.99 |
Piotroski F-Score | 1 |